PABPC1 Antibody

What is PABPC1 and what cellular functions does it perform?

PABPC1 is a cytoplasmic RNA-binding protein that binds to the poly(A) tail of mRNAs, including its own transcript. It regulates multiple processes of mRNA metabolism, including pre-mRNA splicing and mRNA stability . PABPC1 plays a crucial role in translational initiation regulation, which can be enhanced by PAIP1 or repressed by PAIP2 . Recent research has shown that PABPC1 also binds to N6-methyladenosine (m6A)-containing mRNAs and contributes to MYC stability . Additionally, PABPC1 is involved in translationally coupled mRNA turnover and in the regulation of nonsense-mediated decay (NMD) of mRNAs containing premature stop codons . In cardiac tissue, PABPC1 expression is dynamically controlled through poly(A) tail length regulation, which tunes translation capacity during cardiac growth .

What techniques can PABPC1 antibodies be used for in research?

Based on the available research resources, PABPC1 antibodies have been validated for several key laboratory techniques:

• Western Blotting (WB): PABPC1 antibodies show strong performance in Western blot applications with clearly detectable bands at the predicted molecular weight of 71 kDa . Typical working dilutions range from 1/1000 to 1/2500 .

• Immunohistochemistry (IHC-P): PABPC1 antibodies have been validated for paraffin-embedded tissue sections, typically used at dilutions of 1:500 to 1:2500 .

• Co-immunoprecipitation: PABPC1 antibodies can be used to study protein-protein interactions, particularly with translation initiation factors like eIF4G .

• RNA-Protein Interaction Studies: Though not directly using the antibody, techniques like RNA-FISH combined with PABPC1 antibody detection can help determine the cellular localization of PABPC1 mRNA and protein .

How should I select the appropriate PABPC1 antibody for my research?

When selecting a PABPC1 antibody for research, consider these important factors:

• Target Species: Ensure the antibody has been validated in your species of interest. The available antibodies have been validated in human samples , but cross-reactivity with other species should be verified.

• Antibody Type: Available options include polyclonal antibodies raised in rabbit , which offer high sensitivity but may show batch-to-batch variation. Monoclonal antibodies may provide higher specificity.

• Application Compatibility: Verify that the antibody has been validated for your specific application. For example, ab153930 has been validated for Western blotting and IHC-P .

• Target Region: Consider which domain of PABPC1 the antibody recognizes. For instance, ab153930 was raised against a recombinant fragment within human PABPC1 amino acids 350 to the C-terminus .

• Citations: Review published literature that has used the antibody to confirm its performance in similar experimental contexts.

How can I validate the specificity of PABPC1 antibodies in my experimental system?

Validating antibody specificity is critical for ensuring reliable experimental results. For PABPC1 antibodies, consider implementing these validation strategies:

• Knockdown/Knockout Controls: Use siRNA targeting the 3'-UTR of PABPC1 as demonstrated in cardiomyocyte studies . The absence or significant reduction of signal in Western blots or immunostaining following PABPC1 knockdown confirms antibody specificity.

• Overexpression Validation: Express tagged versions of PABPC1 and verify co-localization or signal increase with the PABPC1 antibody. The research shows that adenoviral transduction of PABPC1 constructs can be used as positive controls .

• Multiple Antibody Verification: Compare results using different antibodies targeting distinct epitopes of PABPC1. For example, compare antibodies from different vendors like Abcam (ab153930) and Sigma-Aldrich (HPA045423) .

• Pre-absorption Test: Pre-incubate the antibody with excess purified PABPC1 protein before using it in your application. This should significantly reduce or eliminate specific signals.

• Cell/Tissue Panel Verification: Test the antibody across multiple cell lines with known PABPC1 expression levels. Published data shows successful detection in A549, H1299, HCT116, and MCF7 cell lines .

What methodology should I follow when using PABPC1 antibodies to study its interaction with eIF4G?

Studying PABPC1-eIF4G interactions requires careful experimental design:

• Co-immunoprecipitation Protocol:

  • Expand cells of interest (e.g., C2C12 cells) until 95-100% confluency

  • If needed, introduce wild-type or mutant PABPC1 constructs via adenoviral infection at 5 × 10^9 o.p.u.

  • After appropriate incubation (e.g., 4 days post-infection), wash cells with PBS

  • Lyse cells on ice using an appropriate lysis buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, 0.5 mM EDTA, 10% glycerol, 1% Triton X-100, 5 mM dithiothreitol) supplemented with protease and phosphatase inhibitors

  • Incubate 1-5 mg of cell lysate with 200 μL of anti-Flag magnetic beads slurry at 4°C for 6 hours

  • Wash the beads thoroughly, then separate proteins by SDS-PAGE

  • Transfer to PVDF membranes and probe with anti-eIF4G1 antibody

• Mutational Analysis: Use structural information to design mutations that disrupt specific interactions. For example, the M161A mutation disrupts PABPC1-eIF4G interaction but not poly(A) binding . The mRRM2 mutant variant completely abolishes interaction with eIF4G while maintaining poly(A) RNA binding capacity .

• Functional Validation: Assess the functional consequences of disrupting the PABPC1-eIF4G interaction through rescue experiments. Research shows that wild-type PABPC1, but not the mRRM2 variant, can rescue hypertrophic growth response and protein synthesis in PABPC1-depleted cardiomyocytes .

How can I optimize PABPC1 antibody use for detecting tissue-specific expression patterns?

Optimizing PABPC1 antibody detection in different tissues requires addressing tissue-specific challenges:

• Cardiac Tissue Considerations:

  • Be aware that PABPC1 protein expression is post-transcriptionally silenced in adult human and mouse hearts through shortening of its mRNA poly(A) tail

  • Use appropriate positive controls (such as hypertrophic heart tissue) where PABPC1 is upregulated

  • Consider using more sensitive detection methods for tissues with naturally low expression

• Immunohistochemistry Protocol Optimization:

  • For paraffin-embedded human hepatoma tissue, successful staining has been achieved using ab153930 at 1/500 dilution

  • Optimize antigen retrieval methods based on tissue type

  • Include appropriate positive and negative controls

• Expression Pattern Variability:

  • Note that PABPC1 expression varies significantly between tissue types and physiological conditions

  • In cardiac tissue, PABPC1 is dynamically regulated during hypertrophy

  • Use quantitative approaches (fluorescence intensity measurements, Western blot densitometry) to accurately assess expression level differences

What methods can I use to study PABPC1's role in translation regulation?

To investigate PABPC1's role in translational control:

• Protein Synthesis Measurement:

  • Use metabolic labeling with L-homopropargylglycine (HPG) followed by Click-iT chemistry

  • Wash cultured cells twice with warmed PBS

  • Incubate in methionine-free medium with appropriate stimuli (e.g., isoproterenol or T3) for 1 hour

  • Replace with methionine-free medium containing 50 μM HPG

  • After 60 minutes of incorporation, conjugate newly synthesized proteins with carboxytetramethylrhodamine alkyne (TAMRA)

  • Analyze by SDS-PAGE and visualize using 532 nm excitation

  • Normalize using Coomassie blue staining

• Polysome Profiling:

  • Use sucrose gradient centrifugation to separate mRNAs based on ribosome loading

  • Extract RNA from different fractions and analyze PABPC1 mRNA distribution

  • Compare polysome association of PABPC1 mRNA across different conditions

  • Research has shown reduced polysome association and translation of PABPC1 in adult hearts

• Translation Rescue Experiments:

  • Deplete endogenous PABPC1 using siRNA targeting the 3'-UTR

  • Reintroduce wild-type or mutant PABPC1 via adenoviral transduction

  • Assess restoration of protein synthesis using metabolic labeling

  • Studies show wild-type PABPC1, but not eIF4G-binding deficient mutants, can restore translation

How can I investigate the relationship between poly(A) tail length and PABPC1 expression?

To study the regulatory relationship between poly(A) tail length and PABPC1 expression:

• Poly(A) Tail Length Analysis by Northern Blot:

  • Mix total RNA with 0.5 μM DNA oligonucleotides that hybridize to PABPC1 or control genes like GAPDH

  • Include oligo-dT40 at 0.5 μM where appropriate

  • Incubate at 65°C for 5 minutes, then chill on ice

  • Add RNase H buffer, DTT, poly(A), RNasin, and RNase H

  • Incubate at 37°C for 2 hours

  • Stop the reaction by adding G-50 buffer

  • Extract RNA using phenol:chloroform:isoamyl alcohol

  • Perform northern blot using RNA probes generated by incorporating 32P-UTP

• RNA-FISH to Study mRNA Localization:

  • Design approximately 48 fluorescently labeled oligonucleotide probes targeting PABPC1 mRNA

  • Fix cells in 3.7% formaldehyde buffer in PBS

  • Permeabilize using 70% ethanol for 48 hours at 4°C

  • Perform hybridization with probes overnight at 37°C

  • Wash and counterstain nuclei with DAPI

  • Mount and image using confocal microscopy

• Correlative Studies:

  • Compare poly(A) tail length with protein expression levels across different tissues or conditions

  • Research indicates that PABPC1 expression is post-transcriptionally silenced in adult hearts through shortening of its mRNA poly(A) tail

  • Analyze how physiological stimuli (like hypertrophic signals) affect both poly(A) tail length and PABPC1 protein levels

Why might I observe inconsistent PABPC1 detection across different cell types?

Inconsistent PABPC1 detection across cell types may result from several factors:

• Variable Expression Levels: PABPC1 expression varies naturally across tissues. Adult cardiac tissues show post-transcriptionally silenced PABPC1 expression compared to other tissues .

• Post-Translational Modifications: PABPC1 function is regulated by modifications that may affect antibody recognition in different cellular contexts.

• Isoform Expression: Multiple PABPC1 isoforms (including PABPC1, PABPC2, PABPL1) may be recognized differently by antibodies .

• Fixation and Preparation Methods: Different sample preparation protocols can affect epitope accessibility. For IHC applications, optimize antigen retrieval methods for specific tissue types .

• Antibody Cross-Reactivity: Check if your antibody cross-reacts with related proteins. Some antibodies may detect multiple PABP family members .

To address these issues:

• Test multiple PABPC1 antibodies targeting different epitopes

• Include positive control samples with known PABPC1 expression

• Optimize protein extraction and sample preparation protocols for each cell type

• Consider using orthogonal detection methods to confirm results

What controls should I include when using PABPC1 antibodies for Western blotting?

For reliable Western blot results with PABPC1 antibodies, include these essential controls:

• Positive Control Samples: Include lysates from cells known to express PABPC1. Published data shows successful detection in A549, H1299, HCT116, and MCF7 cell lines .

• Loading Controls: Use housekeeping proteins (β-actin, GAPDH) to confirm equal loading across samples.

• Molecular Weight Marker: PABPC1 has a predicted band size of 71 kDa . Confirm your detected band aligns with this size.

• Knockdown/Knockout Control: Include samples where PABPC1 has been depleted using siRNA or CRISPR technology to confirm band specificity .

• Antibody Specificity Control: Pre-incubate your antibody with recombinant PABPC1 protein before probing your blot to demonstrate that the signal can be competed away.

• Dilution Series: For quantitative analysis, include a dilution series of your positive control to ensure measurements fall within the linear range of detection.

How can PABPC1 antibodies be used to study cardiac hypertrophy?

PABPC1 antibodies can provide valuable insights into cardiac hypertrophy research:

• Monitoring PABPC1 Upregulation: PABPC1 is upregulated during cardiac hypertrophy. Use antibodies to track protein expression changes during disease progression or in response to hypertrophic stimuli like isoproterenol (Iso) or triiodothyronine (T3) .

• Structure-Function Studies: Using PABPC1 antibodies in combination with mutant variants (like PABPC1 mRRM2) can help elucidate which protein interactions are critical for hypertrophic growth. Research shows that PABPC1-eIF4G interactions are essential for cardiomyocyte hypertrophy .

• Mechanistic Insights:

  • Analyze how PABPC1 depletion affects translation of hypertrophic markers like Acta1, Myh7, and Anp

  • Research demonstrates that PABPC1 knockdown inhibits protein but not mRNA upregulation of these markers, indicating PABPC1's specific role in translational control

  • Study the relationship between PABPC1 levels and global protein synthesis rates using metabolic labeling techniques

• Therapeutic Target Validation: As PABPC1-depleted cardiomyocytes are resistant to hypertrophic stimuli, antibodies can help evaluate whether potential therapeutic compounds act by modulating PABPC1 expression or function .

What methodological approaches can be used to study PABPC1's role in RNA metabolism?

PABPC1 antibodies facilitate several approaches to study RNA metabolism:

• Ribonucleoprotein Complex Analysis:

  • Use PABPC1 antibodies for RNA immunoprecipitation (RIP) to identify bound RNA targets

  • Combine with sequencing (RIP-seq) to catalog PABPC1-associated transcripts

  • Focus on specific binding contexts, such as N6-methyladenosine (m6A)-containing mRNAs

• mRNA Stability Assays:

  • Compare mRNA half-lives in PABPC1-depleted versus control cells

  • Focus on transcripts like MYC where PABPC1 contributes to stability by binding to m6A-containing regions

  • Use actinomycin D chase experiments combined with PABPC1 antibody detection to correlate protein levels with target mRNA stability

• Translation Regulation Studies:

  • Analyze how PABPC1 mediates cytoplasmic deadenylation/translational and decay interplay

  • Study its role in nonsense-mediated decay by examining interactions with UPF1 and ribosome-bound release factors

  • Investigate how PABPC1 protects mRNAs from uridylation by ZCCHC6/ZCCHC11

• PABPC1 Autoregulation Analysis:

  • PABPC1 binds the poly(A) tail of its own transcript

  • Use antibodies to study how this autoregulatory loop functions across different physiological conditions

What emerging research areas might benefit from PABPC1 antibody applications?

Several promising research areas could benefit from advanced PABPC1 antibody applications:

• Tissue-Specific Translation Regulation: Further investigation into how PABPC1 expression is dynamically regulated in different tissues, particularly in context-dependent translation control mechanisms .

• Role in Pathological States: Exploring PABPC1's contribution to disease mechanisms beyond cardiac hypertrophy, including cancer progression, where m6A modification and MYC stability are relevant .

• Therapeutic Targeting: Developing approaches to modulate PABPC1 function for potential therapeutic applications in conditions where dysregulated protein synthesis contributes to pathology.

• Viral Infection Studies: Investigating PABPC1's positive regulation of dengue virus replication and potential involvement in other viral life cycles .

• Post-Translational Modification Mapping: Using modified PABPC1 antibodies to detect specific post-translational modifications that regulate PABPC1 function in different cellular contexts.

• Single-Cell Applications: Developing protocols for PABPC1 antibody use in single-cell proteomics to understand cell-to-cell variability in translation regulation.